Rentschler Biopharma Extends Japanese Pact
German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.
Through its “highly productive and fruitful” collaboration with SPI, the Laupheim-based CDMO said it has secured new contracts with Japanese pharmaceutical companies. Going forward, the two cooperation partners will work together with clients to outline projects from early clinical stage up to commercial launch, thereby ensuring optimal service.
As one of the world’s largest biopharmaceutical markets, Japan is an important area of growth for Rentschler Biopharma, CEO Frank Mathias, said, adding that management has been impressed by the Japanese partner’s strong network and extensive experience in contract manufacturing and supply.
Focused exclusively on client projects, Rentschler, which has a US base at Milford, Massachusetts, USA, offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. The company is a bronze sponsor of the exhibition BioJapan 2019, currently being held in Pacifico Yokohama, Japan, where its executives will be giving presentations.
Japan, which is the world’s third largest pharmaceuticals market, is forecast to reach a value of $89-93 billion by 2023. The country’s players are increasingly becoming involved in the biopharmaceuticals segment, including biologics and gene and cell therapies, where start-ups continue to drive the industry’s growth, as Rentschler noted.
In its home market, the German family-owned firm with more than 850 employees has entered a strategic alliance with Leukocare for formulation development and with Rentschler Fill Solutions for fill & finish services in an effort to offer optimal solutions across the entire value chain.